Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Meinian Onehealth Tops Management's Offer for iKang Healthcare

publication date: Nov 30, 2015
Meinian Onehealth Healthcare has bid $1.5 billion to acquire iKang Healthcare, a provider of preventative healthcare services in China. Meinian, iKang's major competitor, is part of an investor group that offered $22 per ADS for iKang. That's 24% higher than iKang's own take-private deal, which proposed $17.80 per ADS. Ligang Zhang, iKang's Chairman who announced his offer in August, said over the weekend he would not sell his iKang shares to the Meinian group, whose offer he called "undoubtedly hostile." More details....

Stock Symbol: (NSDQ: KANG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital